MISTIE ICH Trial

You are here: BIOS

About MISTIE II

MISTIE-II Clinical Trial

Intracerebral hemorrhage (ICH) is the only major stroke subtype without a clearly effective treatment. ICH occurs in over 100,000 Americans yearly. African Americans, Hispanics and Asians are disproportionately affected. ICH is fatal in 30 to 50% of all occurrences, while it leaves the majority of survivors with significant motor and cognitive disability.

MISTIE is a series of clinical trials where neurosurgeons and neurologists are trying to quickly remove this blood clot from the brain using a thrombolytic (MISTIE II and MISTIE III) or a CT-guided endoscope (MISTIE-ICES).

Preliminary results from the MISTIE-II trial have shown that blood clot in the brain can be successfully removed quickly and safely. These early results also suggest that the MISTIE technique reduces the rate of death and improves the patient's neurologic functioning and quality of life in the year following this type of hemorrhagic stroke.

3D CT image of MISTIE treatment dissolving ICH Thus, a new follow-on study, MISTIE-III, has been proposed and is being considered for funding assistance by the US National Institutes of Health. If the grant is approved, this study would enroll 500 patients from about 75-100 medical centers around the world starting in the fall of 2013. If this approach proves to be effective in this large-scale clinical trial, it could dramatically change the way intracerebral hemorrhage is treated throughout the world!